SLC18A2 and neurodegenerative disease: As such, inhibitors targeting VMAT2 induce monoamine depletion within neurons and have been employed in the treatment of neurodegenerative diseases like Huntington’s disease10 and tardive dyskinesia induced by antipsychotic medications11,12.